57
6
5
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T63547 | MEK1/2-IN-2 | ||
MEK1/2-IN-2 是有效的、ATP 竞争性的 MEK1/2 抑制剂,对野生型 MEK1/2 和一组 MEK1/2 突变细胞表现出同等的抑制效果。 | |||
T80543 |
STE-MEK1(13)
ERK Activation Inhibitor Peptide,Ste-MPKKKPTPIQLNP-NH₂ |
ERK | MAPK |
STE-MEK1(13)(Ste-MPKKKPTPIQLNP-NH2)为一细胞渗透性ERK1/2抑制剂,IC50值为13-30μM,可抑制ERK1/2磷酸化。 | |||
T76556 |
MEK1 Derived Peptide Inhibitor 1
|
||
MEK1Derived Peptide Inhibitor 1,一种肽抑制剂,以IC50值30 μM抑制MEK1激活ERK2。适用于细胞渗透性研究。 | |||
T79144 |
PROTAC MEK1 Degrader-1
|
PROTACs | PROTAC |
PROTACMEK1Degrader-1是一种针对MEK1的PROTAC,显示出pIC50值为7.0。该化合物由MEK1抑制剂与von Hippel-Lindau配体构成,能够抑制ERK1/2的磷酸化,并对A375细胞展现出抗增殖活性。 | |||
T76557 |
Myristoyl-MEK1 Derived Peptide Inhibitor 1
|
||
Myristoyl-MEK1 Derived Peptide Inhibitor 1 是MEK1Derived Peptide Inhibitor 1 的豆蔻酰化形式。Myristoyl-MEK1 Derived Peptide Inhibitor 1 抑制ERK 的激活,IC50为 10 μM。 | |||
T72407 | c-Met/MEK1/Flt-3-IN-1 | ||
Antiproliferative against-3 具有良好的抗癌细胞增殖活性,对 Hela、A549 和 MCF-7 的细胞的 IC50值分别为 0.21 µM、0.39 µM 和 0.33 µM。Antiproliferative against-3 (comp 33) 剂量依赖性的诱导 A549 细胞的凋亡,并将细胞阻滞在 G1 期。 | |||
T6636 |
Refametinib
BAY 86-97661,瑞法替尼//瑞美替尼,BAY 869766,RDEA119 |
MEK | MAPK |
Refametinib (RDEA119) 是可口服的、非 ATP 竞争和选择性的 MEK1/MEK2变构抑制剂,IC50分别为 19 和 47 nM。 | |||
T6692 |
TAK-733
TAK733,TAK 733 |
MEK | MAPK |
TAK-733 是选择性 MEK 抑制剂,IC50为 3.2 nM。 | |||
T6131 |
Pimasertib
AS703026,MSC1936369B,N-[(2S)-2,3-二羟基丙基]-3-[(2-氟-4-碘苯基)氨基]-4-吡啶甲酰胺,SAR 245509 |
MEK | MAPK |
Pimasertib (AS703026) 是一种高效选择性和ATP 非竞争性的MEK1/2抑制剂,可用于癌症研究。 | |||
T5857 |
Trametinib (DMSO solvate)
Trametinib DMSO solvate,GSK-1120212 (DMSO solvate),Trametinib dimethyl sulfoxide,JTP-74057 (DMSO solvate) |
Apoptosis; MEK | Apoptosis; MAPK |
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate)) 是一种口服有效的 MEK 抑制剂,抑制 MEK1 和 MEK2 的 IC50分别为 2 nM。它还能激活自噬,诱导凋亡。 | |||
T6843 |
GDC-0623
G-868,GDC0623,RG 7421,MEK inhibitor 1 |
Apoptosis; MEK | Apoptosis; MAPK |
GDC-0623 (RG 7421) 是一种 ATP 竞争性的MEK1抑制剂,Ki 值为 0.13 nM。它对 A375 细胞中 BRAFV600E 的 EC50值为 7 nM,而对 HCT116 细胞中 KRAS (G13D)的 EC50值为 42 nM。 | |||
T6218 |
Selumetinib
ARRY-142886,司美替尼,AZD6244 |
Apoptosis; ERK; MEK | Apoptosis; MAPK |
Selumetinib (AZD6244) 是一种高效选择性的,非 ATP 竞争性的MEK1/2抑制剂, 抑制 MEK1 的IC50为14 nM。它抑制 MEK1/2 磷酸化水平。 | |||
T5412 |
RO4987655
CH4987655,RG7167 |
MEK | MAPK |
RO4987655 (RG7167) 是一种具有口服活性和高选择性的 MEK 抑制剂,抑制MEK1/MEK2,IC50为 5.2 nM。 | |||
T2443 |
CI-1040
PD 184352 |
Apoptosis; MEK | Apoptosis; MAPK |
CI-1040 (PD 184352) 是一种有口服活性的高度特异性MEK 小分子抑制剂,对 MEK1 的IC50值为 17 nM 。 | |||
T2125 |
Trametinib
GSK1120212,曲美替尼,JTP-74057 |
Apoptosis; MEK; Autophagy | Apoptosis; Autophagy; MAPK |
Trametinib (GSK1120212) 是一种 MEK 抑制剂,抑制 MEK1 和 MEK2 (IC50=0.7/0.9 nM),具有 ATP 非竞争性和口服活性。Trametinib 可以激活自噬,诱导凋亡。 | |||
T2708 |
SL327
SL 327,SL-327 |
MEK; DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; MAPK |
SL327 是能通过血脑屏障运输的选择性 MEK1/2 抑制剂,IC50 分别为 0.18 和 0.22 μM。 | |||
T2623 |
PD98059
PD 98059 |
ERK; Aryl Hydrocarbon Receptor; MEK; Autophagy | Autophagy; Immunology/Inflammation; MAPK |
PD98059 是一种 MEK 抑制剂,抑制 MEK1 和 MEK2 (IC50=2/50 μM),具有非 ATP 竞争性。PD98059 也是一种 AHR 的配体而起拮抗作用。PD98059 可以抑制细胞自噬。 | |||
T6223 |
U0126-EtOH
U0126 Ethanol,U0126 |
Mitophagy; Influenza Virus; MEK; Autophagy | Autophagy; MAPK; Microbiology/Virology |
U0126-EtOH (U0126 Ethanol) 是一种非 ATP 竞争性的选择性MEK1和MEK2抑制剂,IC50分别为 72 nM 和 58 nM。U0126-EtOH 可抑制自噬和线粒体自噬。 | |||
T6152 |
PD318088
|
MEK | MAPK |
PD318088 是非 ATP 竞争性的MEK1/2变构抑制剂,是 PD184352 的结构类似物。它在MEK1 活性位点与 ATP 结合位点相邻的区域与 ATP 同时结合,可用于癌症研究。 | |||
T6971 |
Ro 5126766
CH5126766,Avutometinib,VS-6766,RO5126766 |
Raf; MEK | MAPK |
Ro 5126766 (CH5126766) 是双重MEK/RAF 抑制剂,抑制BRAFV600E、CRAF、MEK 和 BRAF,IC50分别为 8.2、56、160 和 190 nM。 | |||
T3623 |
Cobimetinib
可美替尼,考比替尼,RG7420,XL518,GDC-0973 |
Apoptosis; MEK | Apoptosis; MAPK |
Cobimetinib (GDC-0973) 是一种可口服的 MEK1选择性抑制剂,抑制MEK1的IC50为4.2 nM。 | |||
T6083 |
AZD8330
ARRY-424704,ARRY-704 |
ERK; MEK | MAPK |
AZD8330 (ARRY-704) 是非竞争性的 MEK1/MEK2抑制剂,IC50为 7 nM。 | |||
T2253 |
TCS PIM-1 1
3-氰基-4-苯基-6-(3-溴-6-羟基苯基)-2(1H)-吡啶酮,SC 204330 |
Pim | Chromatin/Epigenetic; JAK/STAT signaling |
TCS PIM-1 1 (SC 204330) 是一种特异性有效的 ATP 竞争性 Pim-1 激酶抑制剂,IC50为 50 nM,对 MEK1/MEK2 和 Pim-2 表现出良好的特异性,IC50值大于 20000 nM。 | |||
T2508 |
Binimetinib
ARRY-438162,ARRY-162,MEK162 |
MEK; Autophagy | Autophagy; MAPK |
Binimetinib (ARRY-162) 是一种可口服的选择性 MEK1/2抑制剂,抑制MEK 的IC50为 12 nM。 | |||
T6525 |
GW 5074
GW5074,3-(3,5-二溴-4-羟基苯亚甲基)-5-碘-1,3-二氢吲哚-2-酮,Raf1 Kinase Inhibitor I |
Apoptosis; Raf | Apoptosis; MAPK |
GW 5074 (Raf1 Kinase Inhibitor I) 是一种有效且特异性的 c-Raf 抑制剂,IC50值为 9 nM。 它对 JNK1/2/3、MEK1、MKK6/7、CDK1/2、c-Src、p38 MAP、VEGFR2 或 c-Fms 的活性没有影响。 | |||
T6039 |
TAK-285
TAK285,TAK 285 |
EGFR; MEK; HER; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; MAPK; Tyrosine Kinase/Adaptors |
TAK-285 是一种新型 HER2 和 EGFR(HER1) 双重抑制剂,IC50 分别为 17 和 23 nM。它可穿过血脑屏障,有抗肿瘤活性,对 HER1/2 的选择性是 HER4 的 10 倍以上。 | |||
T6324 |
(E/Z)-BIX02188
334949-59-6 |
ERK; MEK; TGF-beta/Smad | MAPK; Stem Cells |
BIX02188 是一种特异性 MEK5 抑制剂 (IC50: 4.3 nM),也抑制 ERK5 催化活性 (IC50: 810 nM),并且不抑制密切相关的激酶 MEK1/2、JNK2 和 ERK2。 | |||
T27242 |
EF24
EF 24,EF-24,3,5-Bis[(2-fluorophenyl)Methylene]-4-piperidinone |
ERK; MEK; Caspase | Apoptosis; MAPK; Proteases/Proteasome |
EF24 (3,5-Bis[(2-fluorophenyl)Methylene]-4-piperidinone) 是姜黄素类似物,口服生物利用度高,抗肿瘤作用强。它可增强活化的 Caspase3 及 Caspase9 的水平,并抑制 MEK1 及 ERK 的磷酸化形式的表达。它可以抑制口腔鳞状细胞癌细胞的 MAPK/ERK 信号通路,从而发挥抗肿瘤作用。 | |||
T6077 |
ZM-447439
|
Apoptosis; MEK; Src; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; MAPK; Tyrosine Kinase/Adaptors |
ZM 447439是一种极光激酶 (aurora) 抑制剂,对aurora A 和B 的IC50值分别为110和130 nM。 | |||
T6760 |
APS-2-79 hydrochloride
APS-2-79 HCl,APS-2-79 |
MEK; MAPK | MAPK |
APS-2-79 hydrochloride (APS-2-79 HCl) 是一种 KSR 依赖性的MEK 拮抗剂,可与 ATPbiotin 竞争性地结合到 KSR2-MEK1 复合物内的KSR2。它与 KSR 结合可将 KSR 处于非活性状态,使其无法再结合 RAF 和激活 MEK,从而阻断 Ras-MAPK 信号通路。 | |||
T2378 |
RGB-286638 free base
|
GSK-3; MEK; JAK; CDK | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; MAPK; PI3K/Akt/mTOR signaling; Stem Cells |
RGB-286638 free base 是一种新型 CDK 抑制剂,抑制cyclin T1-CDK9、cyclin B1-CDK1、cyclin E-CDK2、cyclin D1-CDK4、cyclin E-CDK3和p35-CDK5活性,IC50分别为 1、2、3、4、5 和 5 nM。它也抑制 GSK-3β、TAK1、Jak2 和 MEK1,IC50值分别为 3、5、50和 54 nM。 | |||
T21635 |
PD184161
|
MEK | MAPK |
PD 184161 是一种口服有效的,时间和浓度依赖的 MEK 抑制剂,IC50为10-100 nM。它诱导抑郁样行为,抑制细胞增殖并诱导细胞凋亡。 | |||
T35610 |
2,5-dimethyl Celecoxib
|
Apoptosis; Wnt/beta-catenin; Prostaglandin Receptor | Apoptosis; Cytoskeletal Signaling; GPCR/G Protein; Immunology/Inflammation; Stem Cells |
2,5-dimethyl Celecoxib 是塞来昔布衍生物和微粒体前列腺素 E 合酶 1 (mPGES-1) 的靶向抑制剂,mPGES-1 是炎症介质 PGE2 合成途径中的关键酶。 | |||
T13782 |
MS432
|
MEK | MAPK |
MS432 is a highly selective PD0325901-based VHL-recruiting PROTAC degrader for MEK1 and MEK2. | |||
T23129 |
PD 334581
|
Others | Others |
MEK1 inhibitor | |||
T63929 |
Selumetinib sulfate
|
||
Selumetinib (AZD6244) 是高效的、选择性的、非 ATP 竞争性的 MEK1/2 抑制剂,可抑制 MEK1/2 磷酸化水平,对 MEK1 的 IC50 值为 14 nM。 | |||
T64175 |
Cobimetinib hemifumarate
|
||
Cobimetinib hemifumarate 是一种有效的、选择性的 MEK1 抑制剂,对 MEK1 的 IC50 值为 4.2 nM。 | |||
T71163 |
Pimasertib HCl
|
||
Pimasertib HCl is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activati... | |||
T64001 | MAP855 | ||
MAP855 是一种高效的、选择性的、口服具有活力的具、 ATP 竞争性的 MEK1/2 激酶抑制剂,对 MEK1 ERK2 cascade 的 IC50 值为 3 nM,pERKEC50 值为 5 nM。MAP855 对野生型和突变型 MEK1/2 表现出同等的抑制效果。 | |||
T78209 |
Nedometinib
|
MEK | MAPK |
Nedometinib是MEK1酪氨酸激酶的抑制剂,具备抗肿瘤活性,适用于皮肤病、皮肤纤维神经瘤和神经纤维瘤病研究。 | |||
T69826 |
U-0126
|
||
U0126 is a highly selective inhibitor of both MEK1 and MEK2, a type of MAPK/ERK kinase. It was found to functionally antagonize AP-1 transcriptional activity via noncompetitive inhibition of the dual specificity kinase MEK with IC50 of 72 nM for MEK1 and 58 nM for MEK2. U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase and mammalian target of rapamycin pathways. | |||
T31126 |
CX-659S
CX659S,UNII-YG2F04AVMQ,CX 659S |
||
CX-659S is a novel diaminuracil derivative that indirectly inhibits Langerhans cell function by blocking the MEK1/2 -- ERK1/2 pathway in keratinocytes. CX-659S can inhibit the contact hypersensitivity induced by haptens in mice. | |||
T28862 |
ST-168
ST168,ST 168 |
||
ST-168 is a potent inhibitor of PI3K and MEK. ST-168 displays improved PI3K and MEK1 isoform inhibition. ST-168 demonstrated a 2.8-, 2.7-, 23-, and 2.5-fold improved inhibition toward the PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ isoforms and a 2.2-fold improvement | |||
T61755 |
E6201
|
||
E6201 (ER-806201) is a potent dual kinase inhibitor targeting MEK1 and FLT3, inhibiting their activities in an ATP-competitive manner. It effectively suppresses MEK1-induced ERK2 phosphorylation (IC50 = 5.2 nM), MKK4-induced JNK phosphorylation (IC50 = 91 nM), and MKK6-induced p38 MAPK phosphorylation (IC50 = 19 nM). E6201 exhibits anti-tumor and anti-psoriasis effects [1] [2]. | |||
T18668 |
(S,R,S)-AHPC-Me-C10-Br
|
Others | Others |
(S,R,S)-AHPC-Me-C10-Br is a chemically synthesized conjugate that functions as a ligand-linker for E3 ligases. This compound incorporates a VHL E3 ligase linker and MS432, derived from the MEK1/2 inhibitor PD0325901[1]. | |||
T68459 |
RO4927350
|
||
RO4927350 is a potent and highly selective non-ATP-competitive MEK1/2 inhibitor. RO4927350 selectively blocks the MAPK pathway signaling both in vitro and in vivo, which results in significant antitumor efficacy in a broad spectrum of tumor models. RO4927350 inhibits not only ERK1/2 but also MEK1/2 phosphorylation. In cancer cells, high basal levels of phospho-MEK1/2 rather than phospho-ERK1/2 seem to correlate with greater sensitivity to RO4927350. Furthermore, RO4927350 prevents a feedback inc... | |||
T68267 | RO5068760 | ||
RO5068760 , a substituted hydantoin, is a potent, highly selective, non-adenosine triphosphate (ATP)-competitive MEK1/2 inhibitors. RO5068760 shows significant efficacy in a broad spectrum of tumors with aberrant mitogen-activated protein kinase pathway activation. In vitro, RO5068760 demonstrates MEK1 kinase inhibitory activity with an IC50 of 0.025 μM in a cRaf/MEK/ERK cascade assay RO5068760 showed superior efficacy in tumors harboring B-RafV600E mutation. | |||
T71722 |
Angiogenesis inhibitor BT2
|
||
Angiogenesis inhibitor BT2 is a novel inhibitor of angiogenesis and vascular permeability, inhibiting ERK phosphorylation and the expression of FosB/ΔFosB, VCAM-1, and many genes involved in proliferation, migration, angiogenesis, and inflammation, interacting with MEK1, suppressing retinal CD31, pERK, VCAM-1, and VEGF-A165 expression. | |||
T74361 | MEK/PI3K-IN-2 | ||
MEK/PI3K-IN-2 (compound 6s) 是一种有效的 MEK/PI3K 抑制剂,其 IC50值分别为 352 nM (MEK1), 107 nM (PI3Kα), 和 137 nM (PI3Kδ)。MEK/PI3K-IN-2 抑制 pAKT 和 pERK1/2 水平。MEK/PI3K-IN-2 对肿瘤细胞具有抗增殖活性。 | |||
T74360 |
MEK/PI3K-IN-1
|
||
MEK/PI3K-IN-1(compound 6r)是一种高效的MEK/PI3K抑制剂,IC50值为124 nM(MEK1)、130 nM(PI3Kα)及236 nM(PI3Kδ)。该化合物能够降低pAKT和pERK1/2的活性,并展现对肿瘤细胞的抗增殖作用。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6S1587 |
Notoginsenoside R2
三七皂苷R2,20(S)-Notoginsenoside R2,Ginsenoside Ng-R2 |
Others; Nrf2 | Immunology/Inflammation; Others |
Notoginsenoside R2 (20(S)-Notoginsenoside R2) 是一种新分离三七皂苷,表现出对6-OHDA 诱导的氧化应激及细胞凋亡的保护作用。 | |||
T5S2361 |
Epiberberine
|
ERK; Beta-Secretase; MEK; BACE; AMPK; AChR; AChE | Chromatin/Epigenetic; MAPK; Neuroscience; PI3K/Akt/mTOR signaling |
Epiberberine 是一种从黄连中得到的生物碱,是AChE 和BChE 抑制剂,和非竞争性BACE1抑制剂。在 3T3-L1 细胞分化早期,它能够下调 Raf/MEK1/2/ERK1/2 和 AMPKα/Akt 信号通路。它具有抗氧化作用,能够清除 ONOO-,可用于阿尔滋海默症和糖尿病的研究。 | |||
T2836 |
Isorhamnetin
3-methylquercetin,3'-Methylquercetin,Isorhamnetol,异鼠李素,3'-Methoxyquercetin |
MEK; PI3K; Endogenous Metabolite | MAPK; Metabolism; PI3K/Akt/mTOR signaling |
Isorhamnetin (3-methylquercetin) 是从中草药沙棘中提取的一种类黄酮,可通过抑制MEK1和PI3K 来抑制皮肤癌。 | |||
T14055 |
5Z-7-Oxozeaenol
FR148083,L783279,LL-Z 1640-2 |
VEGFR; FLT; MEK; MAPK; PDGFR; Antibiotic; Src | Angiogenesis; MAPK; Microbiology/Virology; Tyrosine Kinase/Adaptors |
5Z-7-Oxozeaenol (FR148083) 是一种天然抗原生动物抑制剂,不可逆的选择性抑制 TAK1和 VEGF-R2,IC50值分别为 8 nM 和 52 nM。 | |||
T15542 |
Hypothemycin
|
Others | Others |
Hypothemycin is a fungal polyketide and is a multikinase inhibitor (Kis: 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2, respectively). | |||
T36954 |
Nemorosone
|
||
Nemorosone is a polycyclic polyprenylated acylphloroglucinol (PPAP) originally isolated from C. rosea that has antiproliferative properties.1 Nemorosone inhibits growth of NB69, Kelly, SK-N-AS, and LAN-1 neuroblastoma cells (IC50s = 3.1-6.3 μM), including several drug-resistant clones, but not MRC-5 human embryonic fibroblasts (IC50 = >40 μM).2 It increases DNA fragmentation in LAN-1 cells in a dose-dependent manner, and decreases N-Myc protein levels and phosphorylation of ERK1/2 by MEK1/2. Nem... |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04756 |
MEK1 Protein, Mouse, Recombinant
Prkmk1,MAPKK1,mitogen-activated protein ki... |
Mouse | Baculovirus Insect Cells |
MEK1 Protein, Mouse, Recombinant is expressed in Baculovirus insect cells. The predicted molecular weight is 43.6 kDa and the accession number is P31938. | |||
TMPY-04569 |
MEK1 Protein, Mouse, Recombinant (His & GST)
MEKK1,mitogen-activated protein kinase kin... |
Mouse | Baculovirus Insect Cells |
MEK1 Protein, Mouse, Recombinant (His & GST) is expressed in Baculovirus insect cells with His and GST tag. The predicted molecular weight is 71.3 kDa and the accession number is P31938. | |||
TMPY-04544 |
MEK2 Protein, Human, Recombinant (GST)
mitogen-activated protein kinase kinase 2,FLJ26075,MKK2,CFC4... |
Human | Baculovirus Insect Cells |
Dual specificity mitogen-activated protein kinase kinase 2, also known as MAP kinase kinase 2, MAPKK2, ERK activator kinase 2, MAPK / ERK kinase 2, MEK2 and MAP2K2, is a member of the protein kinase superfamily, STE Ser/Thr protein kinase family and MAP kinase kinase subfamily. MAP2K2 / MEK2 contains one protein kinase domain. MEK1 and MEK2 (also known as MAP2K1 and MAP2K2, respectively) are evolutionarily conserved, dual-specificity kinases that mediate Erk1 and Erk2 activation during adhesion ... | |||
TMPJ-01378 |
Mp1 Protein, Human, Recombinant (His)
Mitogen-Activated Protein Kinase Kinase 1-Interacti... |
Human | E. coli |
Mitogen-Activated Protein Kinase Scaffold Protein 1 (MAPKSP1) was identified as an interacting protein that belongs to the LAMTOR3 family. MAPKSP1 restricted to late endosomes by the mitogen-activated protein-binding protein-interacting protein, and binds specifically to MAP kinase kinase MAP2K1/MEK1, MAP kinase MAPK3/ERK1, and MAP kinase MAPK1/ERK2. MAPKSP1 interacts with MAP2K1/MEK1 and MAPK2 and enhances the activation of MAPK2, and thus is thought to function as an adaptor to enhance the eff... | |||
TMPY-05095 |
RAF1 Protein, Human, Recombinant (His & GST)
Raf-1 proto-oncogene, serine/threonine kinase,CRAF,... |
Human | Baculovirus Insect Cells |
RAF1 gene is the cellular homolog of viral raf gene (v-raf). The encoded protein is a MAP kinase kinase kinase (MAP3K), which functions downstream of the Ras family of membrane associated GTPases to which it binds directly. Once activated, the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2, which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. Activated ERKs are pleiotropic effectors of cell p... |